Clinical Trial

Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This Phase I randomized, double-blind, placebo-controlled clinical trial evaluates the safety and tolerability of PollenVax, a novel recombinant allergen-based vaccine for allergen-specific immunotherapy, in adult patients with mugwort pollen-induced allergic rhinitis.
Protocol Amendment History 1 change
critical Trial completed 2026-06-30
Trial Details
NCT Number NCT07317960
Lead Sponsor Kazakh National Agrarian University
Conditions Rhinitis Allergic
Enrollment 30 participants
Start Date 2025-11-22
Primary Completion 2026-01-16 (estimated)
Study Completion 2026-01-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-29